Byooviz: first ophthalmology biosimilar launches in US

Biosimilars/News | Posted 17/06/2022 post-comment0 Post your comment

Biogen and Samsung Bioepis have launched Byooviz (ranibizumab-nuna) on the US market as the first ophthalmology biosimilar. It references Roche’s (Genentech’s) blockbuster therapy, Lucentis.

VEGF allaboutvision.com V21D02

The ophthalmology biosimilar was approved in the US [1, 2] in September 2021 and had already been approved in Europe in August 2021 [3, 4]. In the US, Byooviz (ranibizumab-nuna) is approved for the treatment of neovascular age-related macular degeneration (nAMD), macular oedema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV) [2].

Ranibizumab is a monoclonal antibody fragment created from the same parent mouse antibody as bevacizumab. Ranibizumab inhibits angiogenesis (the formation of new blood vessels) by inhibiting vascular endothelial growth factor alpha (VEGF-A), a mechanism similar to bevacizumab [5, 6].

The list price will be US$1,130 per single use vial to administer 0.5 mg via intravitreal injection, 40% lower than the current list price of Lucentis.

The originator product Lucentis’ US patent expired in June 2020 and this first biosimilar of it will reach the market on 1 July 2022. In 2021, Lucentis generated global revenue of around US$3.4 billion), with just over 40% of sales in the US. It is hoped that the biosimilar’s launch will be key in increasing options and reducing the financial burden associated with current anti-VEGF treatments and thus increasing accessibility of treatment for patients suffering from retinal vascular disorders.

Related articles
Lucentis biosimilars approved in the UK and Korea

Fresh partnerships announced for ranibizumab and trastuzumab biosimilars

LATIN AMERICAN FORUM

The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View this week’s headline article: El impacto de las insulinas biosimilares en el gasto público brasileño

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

LATIN AMERICAN FORUM

Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de esta semana: El impacto de las insulinas biosimilares en el gasto público brasileño

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 

  

References
1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in the US [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Jun 17]. Available from: www.gabionline.net/biosimilars/general/Biosimilars-approved-in-the-US
2. GaBI Online - Generics and Biosimilars Initiative. Phase III trial evidence used in approval of ranibizumab biosimilar Byooviz [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Jun 17]. Available from: www.gabionline.net/biosimilars/research/phase-iii-trial-evidence-used-in-approval-of-ranibizumab-biosimilar-byooviz
3. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Europe [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Jun 17]. Available from: www.gabionline.net/biosimilars/general/biosimilars-approved-in-europe
4. GaBI Online - Generics and Biosimilars Initiative. EMA recommends approval of Samsung Bioepis Biogen’s ranibizumab biosimilar Byooviz [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Jun 17]. Available from: www.gabionline.net/biosimilars/news/ema-recommends-approval-of-samsung-bioepis-biogen-s-ranibizumab-biosimilar-byooviz
5. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of ranibizumab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Jun 17]. Available from: www.gabionline.net/biosimilars/general/Biosimilars-of-ranibizumab
6. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of bevacizumab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Jun 17]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-of-bevacizumab

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2022 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
FDA approves pegfilgrastim and rituximab biosimilars
18794124_l
Biosimilars/News Posted 24/06/2022
Canada approves five biosimilars in last seven months
Health Canada V13I20
Biosimilars/News Posted 03/06/2022
Lucentis biosimilars approved in the UK and Korea
Age-related macular degeneration V15b19
Biosimilars/News Posted 27/05/2022
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010